McLeod, H.L.

irinotecan patient cancer pharmacokinetic variant polymorphism allele -38 sn -38 genotype paclitaxel ugt 1a frequency transporter population study analysis sn -38g table number haplotype protein diarrhea caucasian plasma ratio metabolite parameter pharmacogenetic effect transport abcc 2 oatp 1b clearance blood signi slco 1b metabolism irinotecan disposition pharmacokinetic parameters association cancer res glucuronidation treatment toxicity activity abcc 2*2 haplotype resistance signi ficantly value sparreboom auc ratio allele frequencies extent research oncol concentration disposition expression ugt 1a allele group 2*2 american variability slco 1b gene slco 1b genotype infusion presence variant type patient 334 t 4g variant allele primer european january volume wild-type paclitaxel clearance exposure article ugt 1a genotype